Capitol Family Office’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.47M Sell
2,060
-114
-5% -$116K 2.61% 6
2026
Q1
$2.34M Hold
2,174
2.76% 8
2025
Q4
$2.34M Sell
2,174
-117
-5% -$112K 2.76% 8
2025
Q3
$1.75M Buy
2,291
+30
+1% +$22.3K 2.12% 9
2025
Q2
$1.76M Sell
2,261
-67
-3% -$52.1K 2.3% 9
2025
Q1
$1.92M Sell
2,328
-736
-24% -$612K 2.72% 9
2024
Q4
$2.37M Sell
3,064
-127
-4% -$105K 3.16% 8
2024
Q3
$2.83M Sell
3,191
-56
-2% -$50.3K 3.5% 9
2024
Q2
$2.94M Sell
3,247
-242
-7% -$194K 3.93% 7
2024
Q1
$2.71M Sell
3,489
-157
-4% -$112K 3.51% 8
2023
Q4
$2.13M Sell
3,646
-192
-5% -$112K 3.58% 11
2023
Q3
$2.06M Buy
+3,838
New +$1.98M 3.88% 10

Other funds holding LLY

Capitol Family Office's LLY Position: Q2 2026 in Review

Capitol Family Office reduced its Eli Lilly (LLY) stake by 5.2% in Q2 2026, selling an estimated $116K and leaving 2,060 shares worth $2.47M. The position accounts for 2.61% of the portfolio, ranked #6.

Capitol Family Office first reported a position in LLY in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.94M in Q2 2024. 2,851 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Capitol Family Office held 2,060 shares of Eli Lilly worth $2.47M as of Q2 2026.
  • Capitol Family Office sold 114 Eli Lilly shares in Q2 2026, an estimated $116K.
  • Eli Lilly made up 2.61% of Capitol Family Office's portfolio in Q2 2026, its #6 holding.
  • Capitol Family Office first reported a position in Eli Lilly in Q3 2023 and has held it in 12 quarters since.
  • Capitol Family Office's Eli Lilly position peaked at $2.94M in Q2 2024.
  • 2,851 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Capitol Family Office's 13F filing for Q2 2026, filed 31 Jul 2026.